Accéder au contenu
Merck
Toutes les photos(3)

Documents

H0252

Sigma-Aldrich

Hydroxyapatite

Type I, buffered aqueous suspension

Synonyme(s) :

Calcium phosphate hydroxide, Durapatite, Hydroxylapatite

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(3)

About This Item

Formule linéaire :
3Ca3(PO4)2 · Ca(OH)2
Numéro CAS:
1306-06-5
Poids moléculaire :
502.31
Numéro CE :
215-145-7
Numéro MDL:
MFCD00010904
Code UNSPSC :
12161700
ID de substance PubChem :
24895395
Nomenclature NACRES :
NA.25

Type

Type I

Niveau de qualité

200

Forme

buffered aqueous suspension

Température de stockage

2-8°C

Chaîne SMILES 

[Ca++].[Ca++].[Ca++].[Ca++].O[Ca+].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O

InChI

1S/5Ca.3H3O4P.H2O/c;;;;;3*1-5(2,3)4;/h;;;;;3*(H3,1,2,3,4);1H2/q5*+2;;;;/p-10

Clé InChI

XYJRXVWERLGGKC-UHFFFAOYSA-D

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Useful in the purification of proteins and nucleic acids

Conditionnement

Package size based on dry weight

Forme physique

Suspension in 0.001 M phosphate buffer, pH 6.8; approx. 25% solids

Code de la classe de stockage

13 - Non Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Gloves

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number
SLBB4937V
069K5304
019K5307
088K5305
016K53071

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Bjarke Viberg et al.
Acta orthopaedica, 84(3), 254-259 (2013-04-19)
Elderly patients with displaced femoral neck fractures are commonly treated with a hemiarthroplasty (HA), but little is known about the long-term failure of this treatment. We compared reoperation rates for patients aged at least 75 years with displaced femoral neck
H S Alghamdi et al.
Journal of dental research, 92(11), 982-988 (2013-09-24)
Osteoporotic conditions are anticipated to affect the osseointegration of dental implants. This study aimed to evaluate the effect of a radiofrequent magnetron-sputtered calcium phosphate (CaP) coating on dental implant integration upon installment in the femoral condyles of both healthy and
Sophie E P New et al.
Circulation research, 113(1), 72-77 (2013-04-26)
We previously showed that early calcification of atherosclerotic plaques associates with macrophage accumulation. Chronic renal disease and mineral imbalance accelerate calcification and the subsequent release of matrix vesicles (MVs), precursors of microcalcification. We tested the hypothesis that macrophage-derived MVs contribute
Ehud Segal et al.
PloS one, 4(4), e5233-e5233 (2009-04-22)
There is an immense clinical need for novel therapeutics for the treatment of angiogenesis-dependent calcified neoplasms such as osteosarcomas and bone metastases. We developed a new therapeutic strategy to target bone metastases and calcified neoplasms using combined polymer-bound angiogenesis inhibitors.
D Mata et al.
Journal of biomedical nanotechnology, 10(5), 725-743 (2014-04-17)
Biomaterials can still be reinvented to become simple and universal bone regeneration solutions. Following this roadmap, a bone graft of carbon nanotube (CNT)/glass/hydroxyapatite (HA) with controlled CNT agglomeration state was designed with multifunctionalities able to stimulate the bone cell phenotype.
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique